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Abstract: Cognitive and mood benefits of coffee are often attributed to caffeine. However, emerging
evidence indicates behavioural effects of non-caffeine components within coffee, suggesting the
potential for direct or synergistic effects of these compounds when consumed with caffeine in regular
brewed coffee. The current randomised, placebo-controlled, double-blind, counterbalanced-crossover
study compared the effects of regular coffee, decaffeinated coffee, and placebo on measures of
cognition and mood. Age and sex effects were explored by comparing responses of older (61–80 years,
N = 30) and young (20–34 years, N = 29) males and females. Computerised measures of episodic
memory, working memory, attention, and subjective state were completed at baseline and 30 min
post-drink. Regular coffee produced the expected effects of decreased reaction time and increased
alertness when compared to placebo. When compared to decaffeinated coffee, increased digit
vigilance accuracy and decreased tiredness and headache ratings were observed. Decaffeinated coffee
also increased alertness when compared to placebo. Higher jittery ratings following regular coffee
in young females and older males represented the only interaction of sex and age with treatment.
These findings suggest behavioural activity of coffee beyond its caffeine content, raising issues with
the use of decaffeinated coffee as a placebo and highlighting the need for further research into its
psychoactive effects.
Keywords: coffee; caffeine; chlorogenic acids; phenolic; cognition; cognitive; mood; age; sex
1. Introduction
Coffee consumption is associated with a number of health benefits in elderly men and
women including reduced risk of cardiovascular disease (CVD) [1], lower incidence of type 2
diabetes mellitus [2], and decreased death from inflammatory diseases [3], CVD [4,5], and all-cause
mortality [6,7]. A number of physiological factors associated with these conditions are relevant to
cognitive function in healthy ageing, as well as pathological ageing conditions such as dementia
or Alzheimer’s disease (AD). Indeed, a number of epidemiological studies have demonstrated
an association between higher coffee consumption and better performance on cognitive tests in
older adults [8,9], as well as an inverse relationship between coffee consumption and risk of
dementia/AD [10–14].
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Cognitive benefits from coffee consumption are typically attributed to caffeine, which exerts its
effects through non-selective antagonism of adenosine A1 and A2A receptors [15]. In support of this,
a number of studies have demonstrated the ability of caffeine to improve measures of attention and
increase ratings of alertness [16–18]. However, coffee contains more than 1000 different compounds
including phenolics, diterpenes, and melanoidins [19], all of which have the potential to affect
behaviour either directly or indirectly through interaction with caffeine. This is demonstrated by
studies showing direct psychoactive effects and modulation of caffeine’s effects by the amino acid
l-theanine, present in tea [20–22]. Similarly, lengthened startled blink onset latency has been shown
following decaffeinated coffee as compared to caffeinated coffee, caffeinated juice, and non-caffeinated
juice [23]. Chlorogenic acids (CGA) are a group of phenolic compounds representing the principal
non-caffeine components in coffee [24] and have been explored in relation to mood and cognition in
healthy, elderly participants [25]. In comparison to regular CGA decaffeinated coffee (224 mg CGA,
5 mg caffeine), high CGA decaffeinated coffee (521 mg CGA, 11 mg caffeine) increased alertness and
decreased negative emotional processing, whereas caffeinated coffee (244 mg CGA, 167 mg caffeine)
increased accuracy on a sustained attention task and improved mood. These results indicate that the
addition of CGA to regular decaffeinated coffee can modulate its effects on behaviour. The effects of
CGA were explored further in a study comparing 540 mg isolated CGA, 6 g decaffeinated green
blend coffee (532 mg CGA), and placebo [26]. Whilst positive effects on mood were observed
following decaffeinated green blend coffee, these effects were not evident following CGA in isolation,
which also led to detrimental effects to cognition at 120 min post-drink. This provides further evidence
for behavioural effects of decaffeinated coffee and highlights the need to consider the synergistic
contribution of non-caffeine compounds in coffee.
Coffee is one of the most widely consumed beverages in the world, yet intervention trials
examining the specific impact of consuming regular, brewed coffee on cognition and mood are lacking.
Given the potential for non-caffeine components within coffee to exert psychoactive effects or to
interact synergistically with caffeine, it is important that the effects of regular coffee and decaffeinated
coffee are compared to placebo. In addition, despite physiological differences between men and
women, including in their nutrient needs and in cognitive performance [27,28], sex differences are
rarely considered in nutritional intervention trials. This is particularly important here, as studies of the
relationship between coffee and cognitive decline have indicated that whilst reduced risk is related to
coffee consumption in men [29], the effect is more pronounced in women [30,31]. This suggests that
greater effects of coffee consumption may be observed in older adults as a consequence of cognitive
decline, and that these beneficial effects may be enhanced in females. Furthermore, given the impact
of the menstrual cycle on resting metabolic rate [32] and systemic clearance of caffeine [33], it is
also possible that sex differences in response will be moderated by age. In order to explore this
further, the current study compared the behavioural effects of regular coffee, decaffeinated coffee
and placebo in elderly participants (61–80 years) to those in a younger (20–34 years) adult group and
examined differential responses in men and women. As debate continues as to whether caffeine’s
effects are modulated by habitual consumption [34,35] only those who regularly consumed coffee and
tea were included.
2. Materials and Methods
2.1. Design
A randomised, placebo-controlled, double-blind, counterbalanced-crossover design was
employed. The study was approved by Northumbria University’s Faculty of Health and Life Sciences
Ethics Committee (reference: SUB057_Forster_090216; approved: 26 February 2016) and was conducted
in accordance with the Declaration of Helsinki.
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2.2. Participants
Seventy-two participants were drawn through an opportunity sample within Newcastle upon
Tyne and the surrounding areas. Thirty-six of these represented an older group aged 61 to 80 years
(18 male), and 36 represented a younger comparator group aged 20 to 34 years (18 male). Sample size
was determined from a power calculation based upon previous data showing improvements to
cognition and mood in habitual caffeine consumers following 150 mg caffeine [16]. An effect size
of d = 0.6 indicated that a total of 72 participants would allow detection of significant effects with a
power of 0.8. All participants were healthy non-smokers for whom English was their first language.
Participants were not currently taking medication with the exception of contraception in young female
participants and those used in the treatment of arthritis, high blood pressure, high cholesterol, and
reflux-related conditions in the older participant group. Due to the potential impact of habitual caffeine
intake on response, only those who regularly consumed more than two cups of coffee or three cups of
tea (equating to ≥150 mg caffeine/day) were included. Participants were paid £60 for taking part.
Thirteen participants were excluded from the per protocol analysis (12 based on high (>1 µg/mL)
pre-dose caffeine salivary levels, and one due to under-consumption of the drink provided).
The population for analysis (see Figure 1) consisted of 30 older adults (14 male) and 29 young (16 males).
Participant characteristics for each age group by sex can be found in Table 1.
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Figure 1. Final participant disposition. N = Number of participants; OF = Older Female; OM = Older 
Male; YF = Younger Female; YM = Younger Male. 
Table 1. Participant demographics (SD = Standard Deviation). 
 Young Older 
 Male Female Male Female 
 Mean SD Mean SD Mean SD Mean SD 
Age 26.3 4.4 26.2 3.6 67.7 6.3 67.1 3.4 
Years in education 18 3 17 3 16 5 14 4 
Body Mass Index (BMI) 25.7 3.8 23.8 3.6 25.9 3.4 26.1 3.9 
Caffeine consumption (mg/day) 327 88.2 351 110.4 426 74.4 394 87.8 
Coffee consumption (cups/day) 2.88 1.54 2.54 1.45 2.64 1.13 3.59 0.93 
Fruit and vegetables (portions/day) 4.3 1.5 4.1 1.4 4.4 1.9 5.4 1.8 
Screening
N = 85 screened 
(OF: 24, OM: 21, YF: 20, YM: 20)
N = 2 failed screening
(OF: 1, OM: 1)
Training
N = 83 completed 
(OF: 23, OM: 20, YF: 20, YM: 20)
Drop-outs 
N = 11
(OF: 5, OM: 2, YF: 2, YM: 2)
N = 72
Randomisation and completion
(OF: 18, OM: 18, YF: 18, YM: 18)
N = 59
Included in analysis
(OF: 16, OM: 14, YF: 13, YM: 16)
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Table 1. Participant demographics (SD = Standard Deviation).
Young Older
Male Female Male Female
Mean SD Mean SD Mean SD Mean SD
Age 26.3 4.4 26.2 3.6 67.7 6.3 67.1 3.4
Years in education 18 3 17 3 16 5 14 4
Body Mass Index (BMI) 25.7 3.8 23.8 3.6 25.9 3.4 26.1 3.9
Caffeine consumption (mg/day) 327 88.2 351 110.4 426 74.4 394 87.8
Coffee consumption (cups/day) 2.88 1.54 2.54 1.45 2.64 1.13 3.59 0.93
Fruit and vegetables (portions/day) 4.3 1.5 4.1 1.4 4.4 1.9 5.4 1.8
2.3. Treatment
At each study visit, one of the following drinks was administered by an independent third party
with no further involvement in the study.
• 220 mL water mixed with 2.5 g coffee flavouring (placebo)
• 220 mL regular coffee (without milk and sugar) containing 100 mg caffeine
• 220 mL decaffeinated coffee (without milk and sugar) containing ~5 mg caffeine
The order in which participants received each drink was determined by computer-generated
random allocation (Latin square) for each sex (male, female) by group (older and younger age
comparators). Regular and decaffeinated coffee were brewed using two separate drip filter coffee
makers following a standardised brewing procedure, including the use of filter papers to minimise
cafestol and kahweol levels. Placebo consisted of 2.5 g flavouring (maltodextrin 2.26 g, dark roast 0.1 g,
mild roast 0.1 g, and coffee natural 0.04 g—Firmenich SA, Meyrin, Satigny, Switzerland) added to
boiling water. Drinks were matched for temperature (58 ◦C) and served in an opaque thermal beaker
with a black opaque straw with 5 min allowed for drinking.
2.4. Salivary Caffeine Levels
Saliva samples were obtained using salivettes (Sarstedt, Leicester, UK). Samples were taken
immediately prior to baseline assessments in order to confirm compliance to abstinence and following
post-drink assessments to confirm effective caffeine absorption. The saliva samples were immediately
frozen at −20 ◦C until thawing. Once thawed, salivette tubes were centrifuged at 15,000× g for
10 min. Stock solutions of caffeine, paraxanthine, and benzotriazole (internal standard) were prepared
in type I ultra-pure water at a concentration of 100 µg/mL. Calibration standards for caffeine and
paraxanthine were prepared between 0.05 and 5.00 µg/mL. Quality control samples were also prepared
at a concentration of 2.5 µg/mL. Internal standard (50 µL at 5.0 µg/mL) was added to 50 µL of each
standard and sample in duplicate. To extract the compounds 2 mL of ethyl acetate was added and
solutions were vortex mixed for 3 min following by centrifugation at 4000× g for 10 min. The organic
layer was transferred to a clean tube and dried under a stream of nitrogen at 45 ◦C. The residue was
reconstituted in 100 µL of mobile phase and 50 µL injected onto the column.
Saliva samples were analysed with high-performance liquid chromatography. The HPLC system
was an Agilent 1260 Infinity™ (Cheadle, Greater Manchester, UK) consisting of an Infinity™ quaternary
pump, an Infinity™ Autosampler with integrated column oven and an Infinity™ multi-wavelength
detector set at 280 nm. Instrument control and data processing was performed using Agilent OpenLab™
CDS (Agilent Technologies Ltd., Cheadle, UK). Chromatographic separation was achieved on a Kinetex
C18 column (4.6 × 250 mm i.d., particle size 5 µm; Phenomenex Ltd., Macclesfield, UK). The mobile
phase consisted of acetonitrile, acetic acid and type I ultra-pure water (5:1:95, v%:v%:v%) delivered at a
flow rate of 1.00 mL/min.
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2.5. Cognitive and Mood Measures
With the exception of driving ability, all cognitive and mood measures were delivered using
the Computerised Mental Performance Assessment System (COMPASS, Northumbria University,
Newcastle upon Tyne, UK), a purpose-designed software application for the flexible delivery
of randomly generated parallel versions of standard and novel cognitive assessment tasks.
This assessment system has previously been shown to be sensitive to nutritional interventions [36,37]
including caffeine [20]. The tasks and mood scales were chosen based on their known sensitivity to
caffeine or susceptibility to ageing. Tasks were presented in the same order on each occasion and, with
the exception of the paper and pencil tasks (immediate and delayed word recall and verbal fluency),
responses were made using a response pad. The entire selection of tasks took approximately 25 min to
complete. See Table 2 for order and scoring of tasks completed at baseline. Due to the potential for
interference from repeat completions, computerised location learning and driving simulation were
only completed post-dose on study visits with the final session from their training day used as the
statistical baseline in the analyses.
Table 2. Cognitive tasks completed at baseline and 30 min post-dose in order of presentation
(computerised location learning and driving ability are described below).
Task Descriptor Scoring Domain
Word presentation
A series of words is displayed on the screen,
one word at a time. In this case, 15 words were
presented with a display time of 1 s and
interstimulus interval of 1 s
-
Immediate word recall
Participants are instructed to write down the
words that were presented. In this case, 60 s
were given to complete the task
Number correct and
number of errors Episodic memory
Picture presentation
A series of photographic images are displayed
on the screen, one at a time. In this case, 15
images were presented with a display time of 2
s and an interstimulus interval of 1 s
-
Simple reaction time
An upwards pointing arrow is displayed on the
screen at irregular intervals. Participants must
respond as quickly as they can as soon as they
see the arrow appear. In this case, 50 stimuli
were presented
Reaction time (ms) Attention
Digit vigilance
A fixed number appears on the right of the
screen and a series of changing numbers
appear on the left of the screen at the rate of
150 per minute. Participants are required to
make a response when the number on the left
matches the number on the right. In this case
the task lasted for 3 min
Accuracy (%), reaction
time for the correct
responses (ms) and false
alarms (number)
Attention
Numeric working
memory
Five single target numbers are displayed on the
screen, one at a time. Participants are required
to memorise these numbers as they appear.
Once the target series has been presented,
numbers are displayed one at a time and
participants are required to indicate if each
number was presented in the previous list or
not. In this case, three trials were completed
Accuracy (%) and
reaction time for the
correct responses (ms)
Working memory
Verbal fluency
Participants are presented with a letter on
screen and asked to write down as many words
as they can, beginning with that letter. In this
case, the letters presented were A, T, C, F, M,
and S and 60 s were given to complete the task
Number correct
permitted words, with
names and
perseverations
discounted from the total
score
Language
Delayed word recall
Participants are instructed to write down the
words that were presented to them at the
beginning of the assessment. In this case, 60 s
were given to complete the task
Number correct and
number of errors Episodic memory
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Table 2. Cont.
Task Descriptor Scoring Domain
Rapid visual information
processing
A continuous series of single digits are
presented in the centre of the screen at the rate
of 100 per minute. Participants are required to
make a response when three consecutive odd
or three consecutive even digits are displayed.
In this case, the task lasted for 5 min, with eight
correct target strings presented in each minute.
Accuracy (%), reaction
time for the correct
responses (ms) and false
alarms (number)
Attention
Delayed word
recognition
All target words that were shown during Word
presentation plus an equal number of decoys
are displayed on the screen one at a time.
Participants indicate if they remember seeing
the word earlier or not.
Accuracy (%) and
reaction time for the
correct responses (ms)
Episodic memory
Delayed picture
recognition
All target pictures shown during Picture
presentation plus an equal number of decoys
are displayed on the screen one at a time.
Participants indicate if they remember seeing
the picture earlier or not.
Accuracy (%) and
reaction time for the
correct responses (ms)
Episodic memory
2.6. Caffeine Research Visual Analogue Scales
Prior to cognitive assessment, subjective state was assessed with the Caffeine Research Visual
Analogue Scales [38], which have previously been used in caffeine research [16,21,39]. The following
descriptors are presented on-screen: ‘relaxed’, ‘alert’, ‘jittery’, ‘tired’, ‘tense’, ‘headache’, ‘overall mood’,
and ‘mentally fatigued’. Participants are asked to rate how much these descriptors match their current
state by placing an ‘x’ on a line with the end points labelled ‘not at all’ (left hand end) and ‘extremely’
(right hand end); with the exception of ‘headache’, which is labelled ‘no headache’ and ‘extreme
headache’; and ‘overall mood’, which is labelled ‘very bad’ and ‘very good’. Ratings are scored as %
along the line from left to right.
2.7. Computerised Location Learning—Learning Phase
Location learning was assessed with a computerised task modified from Kessels et al. [40].
Participants are shown a grid containing pictures of objects. Following a timed delay they are shown
an empty grid and asked to relocate the objects to the correct location shown to them previously. In
the current study, this was repeated five times during the learning phase, with objects presented for
15 s, a gap of 10 s before the empty grid was shown, and a pause of 5 s between each trial. For each
of the five learning trials, a displacement score is calculated as the sum of the errors made for each
object (calculated by counting the number of cells the object had to be moved both horizontally and
vertically in order to be in the correct location) from each trial. A learning index is also calculated as
the average relative difference in performance between trials [((A − B)/A + (B − C)/B + (C − D)/C +
(D − E)/D)/4].
2.8. Computerised Location Learning—Delayed Trial
During the delayed trial, which took place 30 min after completion of the learning phase,
participants are again asked to place the objects in the correct location on the empty grid with no
further prompting. The delayed trial is scored for displacement and delayed recall, which is calculated
as the difference between displacement score on the final learning trial and the delayed trial.
2.9. Driving Ability
A PC based driving simulation (Driving Simulator 2013, Excalibur Publishing Limited, Banbury
Oxfordshire, UK) was used to assess driving ability. Driving was controlled via a steering wheel and
pedals with gears set to fully automatic. The task lasted for 3 min and is scored on the basis of adhering
to road rules and driving ability. Specifically, the task is scored for errors, which are given when
Nutrients 2018, 10, 1386 7 of 18
deviating too much from the track; deviating too much from the instructed directions; not indicating;
speeding; colliding. If the drive ended (either because of collision or because of exceeding 10 errors)
the task was restarted but no more than two restarts (three drives in total) were allowed.
2.10. Procedure
Potential participants attended the Brain Performance and Nutrition Research Centre at
Northumbria University for an initial screening session where they gave informed consent prior to
participation. Their eligibility was assessed in accordance with the criteria outlined in the ‘Participants’
section and training on the computerised tasks was provided. This consisted of five completions of
cognitive tasks and took place on a single day. Participants attended three study visits, separated
by at least seven days to allow for washout and to prevent confound due to caffeine abstention
instructions. These instructions required abstention from caffeine from noon the day before study
visits but this did not exceed 24 h in order to minimise any potential withdrawal effects. Consumption
of alcohol and over-the-counter medication was also restricted for 24 h (48 h in the case of systemic
antihistamines). On the morning of study visits, participants ate their usual breakfast at least 1 h
prior to arrival at the laboratory with the time and composition of breakfast standardised across
visits. Participants attended the laboratory at 9:45 a.m. and were screened to ensure eligibility for
testing that day, this included checking they were in good health and had adhered to instructions
regarding breakfast consumption, and caffeine, alcohol, and medication restrictions. A food diary was
used to aid with breakfast standardisation and a saliva sample was obtained to confirm adherence to
caffeine abstention instructions. All testing took place in a suite of dedicated temperature-controlled
university laboratories with participants visually isolated from each other and wearing noise-reduction
headphones to decrease the impact of any auditory distractions. Baseline assessments of cognition and
mood were completed and participants were then given their drink for that day. After 30 min of rest in
the laboratory, the learning phase of a computerised Location Learning Test (cLLT) was completed
before parallel versions of the tasks completed at baseline. This was followed by the delayed trial of the
cLLT, a driving simulation task and a final saliva sample for assessment of caffeine levels. At the end
of the final visit only, participants were asked to guess which drink they believed they had consumed
that day. See Figure 2 for a schematic depicting the study visit running order.
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2.11. Statistics
The post-dose outcome measures were modelled using the MIXED procedure in SPSS (version 24.0,
IBM Corp., Armonk, NY, USA) which included the respective baseline values and the terms treatment,
age, sex, treatment × age, treatment × sex and treatment × age × sex as fixed factors. In the case
of co puterised location learning and driving simulation, baseline values were taken from the final
training session. Significant effects were followed up with Bonferroni corrected pairwise comparisons.
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3. Results
3.1. Treatment-Related Effects
3.1.1. Salivary Caffeine
Baseline salivary caffeine values were 0.17 µg/mL, confirming adherence to caffeine abstention
instructions. A significant main effect of treatment was observed on post-dose salivary caffeine
(F(2, 101.1) = 155.6, p < 0.0001). Pairwise comparisons revealed significantly greater levels following
caffeinated coffee compared to placebo (p < 0.0001) and decaffeinated coffee (p < 0.0001). See Figure 3.
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Figure 3. Adjusted means + standard error for salivary caffeine measured in µg/mL. Significant
treatment effect **** p < 0.001.
3.1.2. Digit Vigilance
A significant main effect of treatment was observed for digit vigilance accuracy (F(2, 101.1) = 4.44,
p = 0.014). Pairwise comparisons revealed significantly greater accuracy following regular coffee
compared to decaffeinated coffee (p = 0.01). See Figure 4a.
Digit vigilance reaction time was also significantly affected by treatment (F(2, 71.3) = 5.07,
p = 0.009). Pairwise comparisons revealed significantly faster responses following regular coffee
compared to placebo (p = 0.009). See Figure 4b.
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treatment. (a) Digit vigilance accuracy; (b) Digit vigilance reaction time; (c) Rapid Visual Information
Processing (RVIP) reaction time. Accuracy is measured as % and reaction time in milliseconds. * p < 0.05;
** p < 0.01.
3.1.3. Rapid Visual Information Processing
Rapid visual information processing reaction time showed a significant effect of treatment
(F(2, 102.9) = 3.77, p = 0.026). This was due to significantly faster responses following regular coffee
compared to placebo (p = 0.02). See Figure 4c. A significant treatment x sex interaction was also
observed for false alarms (F(2, 93.3) = 4.55, p = 0.013) but pairwise comparisons revealed no
significant effects.
3.1.4. Computerised Location Learning Delayed Trial
Computeri d location learning recall show d a significant treatme t x sex i te action
(F(2, 104) = 3.46, p = 0.035). However, pairwise comparisons revealed no significant effects.
. .5. Alert
Rat ngs of ‘alertness’ were significantly affecte by treatment , 106) = 9.86, p < 0. 001). Thi was
due to significantly higher ratings following regular coffee (p < 0.0005) a d e a inated coffee
(p = 0.0048) compared to placebo. See Figure 5a.
3.1.6. Tired
A significant main effect of treatment on ‘tired’ ratings was also observed (F(2, 101.4) = 12.31,
p = 0.0001). Pairwise comparisons revealed this was due to significantly lower ratings following
regular coffee compared to decaffeinated coffee (p = 0.003) and placebo (p < 0.0001). See Figure 5b.
3.1.7. Headache
A significant main effect of treatment on headache ratings (F(2, 92.9) = 6.31, p = 0.003) was due to
significantly lower ratings following regular coffee compared to decaffeinated coffee (p = 0.0049) and
placebo (p = 0.015). See Figure 5c.
3.1.8. Overall Mood
‘Overall mood’ was significantly affected by treatment (F(2, 105.8) = 5.56, p < 0.005). This was due
to significantly higher ratings following regular coffee compared to placebo (p = 0.004). See Figure 5d.
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3.1.9. Mental Fatigue
A significant main effect of treatment on ‘mental fatigue’ ratings was also observed
(F(2, 97.5) = 4.43, p = 0.014). Pairwise comparisons revealed this was due to significantly lower ratings
following regular coffee compared to placebo (p = 0.01). See Figure 5e.
3.1.10. Jittery
A significant treatment × age × sex interaction was observed on jittery ratings (F(3, 76.2) = 3.01,
p = 0.035). Pairwise comparisons revealed significantly higher ratings following regular coffee
compared to placebo in young females (p = 0.046) and compared to decaffeinated coffee in older
males (0.045). See Figure 5f.
Unadjusted means, standard deviations, and F and p values for all factors (treatment, age, sex)
and their interactions can be found in Tables S1–S3.Nutrients 2018, 10, x 10 of 17 
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Figure 5. Adjusted means + standard error for those mood measures showing significant
treatment-related effects. (a) Alert; (b) Tired; (c) Headache; (d) Overall mood; (e) Mental fatigue;
(f) Jittery. Ratings are measured as % along a visual analogue scale with higher values indicating
greater response. YM = young male; YF = young female; OM = older male; OF = older female; * p < 0.05;
*** p < 0.005; **** p < 0.001.
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3.2. Treatment Guess
Seventy-one percent of participants correctly guessed which drink they had received at the final
visit. Eighty-one percent correctly guessed they had received regular coffee, 72% correctly identified
decaffeinated coffee, and 58% were able to correctly identify placebo as their final drink.
4. Discussion
Consumption of 220 mL of regular coffee containing 100 mg caffeine led to faster responses
during digit vigilance and rapid visual information processing tasks when compared to placebo, and
to increased digit vigilance accuracy when compared to decaffeinated coffee. In terms of mood effects,
ratings of alertness and overall mood were higher and mental fatigue ratings lower following regular
coffee compared to placebo. Tiredness and headache ratings were lower following regular coffee
compared to placebo and decaffeinated coffee. Rating of jitteriness was the only outcome to show
an interaction with sex and age indicating higher ratings following regular coffee when compared to
placebo in young females and when compared to decaffeinated coffee in older males. Decaffeinated
coffee also engendered an increase in subjective alertness, compared to placebo, whereas accuracy
of digit vigilance and tired and headache ratings were impaired in comparison to regular coffee.
A beneficial effect of decaffeinated coffee was also observed following a treatment × age × sex
interaction, which indicated that ratings of jitteriness were significantly lower following decaffeinated
compared to regular coffee in older men. The pattern of response to decaffeinated coffee generally fell
between responses to regular coffee and placebo. Specifically, numeric working memory accuracy and
reaction time, reaction time for attention tasks and mood ratings, all followed the order of placebo >
decaffeinated > regular coffee (see Supplementary Tables), with the exception of relaxed and tense
ratings which showed a preferential effect of decaffeinated coffee.
The findings with regards regular coffee are largely in line with the reported effects of
caffeine, which only has a consistent beneficial effect on attention task performance and subjective
alertness/arousal [16–18]. Whilst this could be taken as support for the notion that caffeine is the
sole contributor to the effects, the finding of psychoactive effects of decaffeinated coffee, in terms of
increased alertness when compared to placebo and a pattern of lower effects than regular coffee in
comparison to placebo, supports the suggestion of a modulatory role for the non-caffeine compounds
within coffee. The effects of decaffeinated coffee presented here are broadly in line with previous
results showing impairment to accuracy of a sustained attention task in comparison to regular
coffee [25] and increases in alertness when compared to placebo and the phenolic acid CGA in
isolation [26]. Previous studies have highlighted CGA as a potentially important component of coffee.
However, whilst there is some evidence for beneficial modulation of coffee’s effects by increasing CGA
content [25], the effects of CGA in isolation were largely negative [26]. This potentially highlights
an issue in applying a reductionist approach to nutritional interventions where complex interactions
between many different components may be required to see optimum results. Although composition
is varied depending on roasting and brewing techniques, caffeine generally only accounts for ~1%
and CGA ~10% of the weight of coffee beans, this leaves almost 90% of the constituents unaccounted
for. It is also important to note that the CGA profile may be altered as part of the decaffeination
process and therefore any analysis of effects must take account of the impact of decaffeination on other
constituents [41].
The observed benefits for regular coffee are expected due to the known effects of caffeine
in antagonising adenosine A1 and A2A receptors thereby, increasing oxygen metabolism [42] and
upregulating various neurotransmitters including noradrenaline, dopamine, serotonin, acetylcholine,
glutamate, and GABA [15]. Caffeine and its metabolites also have a number of mechanistic properties
that make them liable to have a modulatory or interactive effect when caffeine is co-consumed with
other bioactive compounds. These include the inhibition of enzymes involved in the breakdown of
neurotransmitters (e.g., acetylcholinesterase and monoamine oxidase) and cellular signalling molecules
(e.g., phosphodiesterase and PARP (poly(ADP-ribose)polymerase)) [43,44] and a role as a competitive
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substrate for a number of cytochrome P450 (CYP) enzymes (CYP2A1, CYP2E1, and CYP1A1) that
metabolise endogenous and exogenous chemicals in the human body [45–47]. Of particular relevance
here, low-doses of caffeine have therefore been shown to increase the bioavailability of phenolic
compounds [48–50] and have a synergistic effect in terms of the cardiovascular benefits of polyphenols.
Coffee also has the potential to impact glucose metabolism as evidenced by an increase in insulin
sensitivity observed following decaffeinated coffee when compared to placebo [51]. Interestingly,
this effect was not apparent following regular coffee, which may be due to counteractive effects of
caffeine and non-caffeine components within regular coffee. Support for this comes from data showing
decreased insulin sensitivity following caffeine [52]. Moreover, area under the curve (AUC) profiles
for serum insulin indicate that caffeine increases AUC when compared to decaffeinated coffee and
placebo, whilst regular coffee produced a trend towards the same when compared to decaffeinated
coffee, with similar profiles evinced for glucose AUC [53]. CGA derivatives have been shown to
increase insulin sensitivity in rats [54], and further support for the role of phenolic compounds in this
effect comes from data showing modulation of glucose and insulin response following phenolic-rich
berries [55–57] as well as a reduction in the postprandial blood glucose response following grape
seed extract [58]. Similarly, caffeine is known to have a vasoconstrictive effect, including reduced
cerebral blood flow (CBF) [39], whereas phenolic-rich foods have demonstrated the opposite effect.
Of particular relevance is the ability of phenolic-rich cocoa to increase CBF when compared to a
phenolic-poor control matched for methylxanthine content [59,60]. These findings indicate the ability
of coffee components to counteract the negative effects of caffeine and a potential synergy whereby
phenolic compounds increase CBF, and therefore oxygen supply, whilst caffeine increases brain activity
and subsequent oxygen metabolism. It is also possible that caffeine increases absorption of phenolics
as has been shown following consumption of cocoa [48] but is as yet untested following coffee.
A further consideration is that due to a focus on psychoactive effects of caffeine, the cognitive
and mood effects of coffee have typically been measured at 30 to 120 min post-dose coinciding with
a peak in caffeine levels at around 40-min post-ingestion [61]. However, analysis of the fate of CGA
following coffee consumption shows that whilst a number of phenolic acids and their derivatives
peak between 30 and 60 min, others do not appear until between 4- and 6-h post-ingestion [62].
It is therefore necessary to extend the testing period in order to fully examine the impact of these
metabolites. This is also true in relation to caffeine, which has a half-life of around 5 h [63], and has
demonstrated behavioural effects up to 8 h post-dose [64]. It is therefore probable that any effects of
coffee observed at 6-h would represent an interaction between phenolic acids and caffeine and the
measurement of biomarkers would aid in elucidating the role of each.
Learning and episodic memory tasks showed the expected effect in terms of significantly lower
performance in the older cohort when compared to young (see Supplementary Tables). However,
no interactions between age and treatment were observed on any cognitive measure. Whilst learning
and memory are not typically susceptible to caffeine, it has been proposed that these tasks may show
sensitivity in low arousal situations as is expected in the elderly as energetic resources diminish [65].
However, in the current study there was no evidence of higher arousal in the young sample when
compared to the older participants on subjective measures of ‘arousal’ or psychomotor tasks. This may
suggest that the older cohort studied here were relatively high functioning, as is supported by their
status being higher than national averages both in relation to fruit and vegetable consumption and
education level [66]. It has also been suggested that cognitive benefits of caffeine consumption
may be more pronounced in those aged over 80 years [31,67]. Therefore, the findings reported here
do not preclude interaction effects in an older sample with poorer nutritional status and/or lower
education level.
Similarly, although sex differences were observed in the current study, these did not interact
with treatment as may have been expected from data showing greater benefits of coffee consumption
in women than men [30]. However, the potential mechanisms underlying sex differences following
habitual consumption, including sex steroid levels [68,69], haemodynamic mechanisms [70], and uric
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acid responses [71,72], are unlikely to exert effects over a 30-min time period. Furthermore, given
the impact of the menstrual cycle and hormonal contraception on metabolism, it is possible that any
differential sex effects in the younger cohort were obscured by the lack of control for menstrual cycle
phase and the inclusion of four hormonal contraceptive users in this study. This also potentially
explains large variations in salivary caffeine following regular coffee in young females that were not
observed in the young male group. Similar large variations in response were shown for older men
and women indicating individual differences in response to caffeine. This variability is largely due to
differences in CYP1A2 activity, which is influenced by a number of factors including sex and genetic
polymorphisms [73].
Polymorphisms of the ADORA2A gene may only explain the age, sex, treatment interaction,
which indicated that older men and younger women experienced greater feelings of jitteriness
following regular coffee. It has previously been reported that those who are T/T homozygous
at nucleotide positions 1976C > T and 2592Tins experience increases in anxiety after caffeine
administration that are not observed in the other genotypic groups [74,75]. Moreover, sex differences
in response have been noted for 1976TT homozygotes, whereby females are more susceptible to
anxiogenic effects of caffeine than males [76,77]. Interestingly, whilst there is evidence for reduced
caffeine intake in 1976TT homozygotes [78], others have shown that intake of coffee, but not other
sources of caffeine, is increased. It was also shown that increased habitual consumption moderated
anxiogenic effects of caffeine such that they were only observed in non/light consumers of caffeine,
irrespective of genotype [79]. This indicates that even in those with a genetic predisposition, tolerance
to anxiogenic effects can occur with habitual consumption. As the older men in the current study
consumed less coffee than their female counterparts, this may in part explain the specificity of ‘jittery’
effects observed here. However, there are a multitude of factors that impact on interindividual
differences [80], which require further exploration before definitive conclusions can be reached.
In the current study, although the addition of a true placebo builds on research previously limited
to comparing effects following caffeinated and decaffeinated coffee, one important limitation is the
omission of a caffeine-only arm. The inclusion of a caffeine-only condition would have allowed a
direct comparison of any synergistic effects between caffeine and the other bioactive compounds
in coffee, including the phenolic compounds. It may also have facilitated in blinding of drinks.
Although the placebo drink in the current study was somewhat effective in that 42% incorrectly
identified it, only 1 of 19 participants mistook it for regular coffee. It is important to note that this
measure was only included at the end of the final visit when all three drinks had been consumed and,
therefore, does not rule out the blinding of participants at earlier visits. However, as the stimulant
effects of caffeine are easily detected, the inclusion of a caffeine-containing ‘placebo’ would provide an
active control for regular coffee and reduce the ability of participants to correctly identify regular coffee.
The findings presented here suggest behavioural activity of coffee beyond its caffeine content.
In fact, only one cognitive measure and two subjective measures showed significant differences
between regular and decaffeinated coffee in favour of regular coffee. This highlights two key issues
with studies which compare regular and decaffeinated coffee. Firstly, these studies attribute any
differential effects to caffeine without considering the potential for interaction with other components.
Secondly, any synergistic effects of caffeine and other coffee components within regular coffee are
likely to be underestimated due to the potential for behavioural effects of decaffeinated coffee used as
the control. If the effects of regular coffee are to be fully understood, it is important that future research
compares these to the equivalent dose of caffeine, decaffeinated coffee, and placebo. Furthermore,
research in this area must include plasma levels of potentially important compounds, including
phenolic compounds. This would allow assessment of the impact of caffeine on the pharmacodynamic
profile of other components in coffee. An extended testing period is also recommended in order to
capture effects of colonic metabolites of phenolics appearing at ~8 h. Further research is also required
in which cognition is measured alongside potential underlying mechanisms including, but not limited
to, glucoregulation and modulation of cerebral haemodynamics. Finally, in order to capture the impact
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of interindividual differences in metabolism of caffeine and other components of coffee on behavioural
outcomes, genetic factors should also be considered.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/10/10/1386/
s1, Table S1: saliva; Table S2: cognition; Table S3: mood.
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